IQVIA Holdings Inc. (0JDM.L)
USD 154.65
(-3.4%)
USD 154.65
(-3.4%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 20.56 Billion USD | 5.09% |
| 2022 | 19.57 Billion USD | 4.96% |
| 2021 | 18.64 Billion USD | 1.99% |
| 2020 | 18.28 Billion USD | 7.63% |
| 2019 | 16.98 Billion USD | 8.93% |
| 2018 | 15.59 Billion USD | 8.42% |
| 2017 | 14.38 Billion USD | 16.49% |
| 2016 | 12.34 Billion USD | 189.72% |
| 2015 | 4.26 Billion USD | 6.29% |
| 2014 | 4 Billion USD | 7.38% |
| 2013 | 3.73 Billion USD | -3.21% |
| 2012 | 3.85 Billion USD | 17.18% |
| 2011 | 3.29 Billion USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 20.23 Billion USD | -1.65% |
| 2024 Q3 | 20.21 Billion USD | 2.69% |
| 2024 Q2 | 19.68 Billion USD | -2.7% |
| 2023 Q2 | 20.28 Billion USD | 2.43% |
| 2023 Q4 | 20.56 Billion USD | 1.97% |
| 2023 FY | 20.56 Billion USD | 5.09% |
| 2023 Q3 | 20.17 Billion USD | -0.57% |
| 2023 Q1 | 19.8 Billion USD | 1.2% |
| 2022 FY | 19.57 Billion USD | 4.96% |
| 2022 Q3 | 18.87 Billion USD | -0.97% |
| 2022 Q1 | 19.05 Billion USD | 2.16% |
| 2022 Q2 | 19.06 Billion USD | 0.06% |
| 2022 Q4 | 19.57 Billion USD | 3.69% |
| 2021 Q1 | 18.23 Billion USD | -0.3% |
| 2021 FY | 18.64 Billion USD | 1.99% |
| 2021 Q2 | 18.17 Billion USD | -0.29% |
| 2021 Q4 | 18.64 Billion USD | 2.43% |
| 2021 Q3 | 18.2 Billion USD | 0.15% |
| 2020 Q3 | 17.73 Billion USD | 2.3% |
| 2020 Q4 | 18.28 Billion USD | 3.12% |
| 2020 Q1 | 17.27 Billion USD | 1.7% |
| 2020 Q2 | 17.33 Billion USD | 0.32% |
| 2020 FY | 18.28 Billion USD | 7.63% |
| 2019 Q4 | 16.98 Billion USD | 2.97% |
| 2019 Q3 | 16.49 Billion USD | 1.3% |
| 2019 Q2 | 16.28 Billion USD | 0.26% |
| 2019 Q1 | 16.24 Billion USD | 4.16% |
| 2019 FY | 16.98 Billion USD | 8.93% |
| 2018 Q1 | 14.78 Billion USD | 2.77% |
| 2018 FY | 15.59 Billion USD | 8.42% |
| 2018 Q4 | 15.59 Billion USD | 3.7% |
| 2018 Q3 | 15.03 Billion USD | 0.17% |
| 2018 Q2 | 15.01 Billion USD | 1.56% |
| 2017 FY | 14.38 Billion USD | 16.49% |
| 2017 Q1 | 13.38 Billion USD | 8.38% |
| 2017 Q3 | 14.93 Billion USD | 6.64% |
| 2017 Q4 | 14.38 Billion USD | -3.71% |
| 2017 Q2 | 14 Billion USD | 4.67% |
| 2016 Q1 | 4.18 Billion USD | -1.72% |
| 2016 FY | 12.34 Billion USD | 189.72% |
| 2016 Q4 | 12.34 Billion USD | 193.25% |
| 2016 Q3 | 4.21 Billion USD | 0.46% |
| 2016 Q2 | 4.19 Billion USD | 0.06% |
| 2015 Q2 | 4.04 Billion USD | 5.05% |
| 2015 Q1 | 3.84 Billion USD | -4.01% |
| 2015 FY | 4.26 Billion USD | 6.29% |
| 2015 Q4 | 4.26 Billion USD | 1.15% |
| 2015 Q3 | 4.21 Billion USD | 4.21% |
| 2014 Q4 | 4 Billion USD | 10.07% |
| 2014 Q2 | 3.6 Billion USD | -0.58% |
| 2014 Q1 | 3.62 Billion USD | -3.02% |
| 2014 FY | 4 Billion USD | 7.38% |
| 2014 Q3 | 3.64 Billion USD | 1.19% |
| 2013 Q1 | 3.74 Billion USD | -2.83% |
| 2013 Q2 | 3.44 Billion USD | -8.08% |
| 2013 Q3 | 3.55 Billion USD | 3.13% |
| 2013 FY | 3.73 Billion USD | -3.21% |
| 2013 Q4 | 3.73 Billion USD | 5.07% |
| 2012 FY | 3.85 Billion USD | 17.18% |
| 2012 Q4 | 3.85 Billion USD | 0.0% |
| 2011 FY | 3.29 Billion USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | -3196.214% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -7669.656% |
| bluebird bio, Inc. | 424.62 Million USD | -4744.05% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -29814.629% |
| Editas Medicine, Inc. | 150.05 Million USD | -13607.549% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | -486.765% |
| Myriad Genetics, Inc. | 312.9 Million USD | -6473.666% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 60.356% |
| Biogen Inc. | 12.04 Billion USD | -70.762% |
| Nektar Therapeutics | 267.04 Million USD | -7602.418% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -16211.787% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -3229.901% |
| Imunon, Inc. | 8.53 Million USD | -241025.093% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -1917.756% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -4119.62% |
| Verastem, Inc. | 71.18 Million USD | -28795.132% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 70.128% |
| Waters Corporation | 3.47 Billion USD | -491.656% |
| Perrigo Company plc | 6.04 Billion USD | -240.479% |
| Dynavax Technologies Corporation | 375.02 Million USD | -5384.716% |
| Illumina, Inc. | 4.36 Billion USD | -371.118% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -58372.675% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -10408.435% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -7919.76% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -55056.602% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | -988.276% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -24852.386% |
| Evolus, Inc. | 209.68 Million USD | -9709.383% |
| Adicet Bio, Inc. | 37.12 Million USD | -55312.177% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -51033.595% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | -189.415% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -3012.789% |
| FibroGen, Inc. | 585.72 Million USD | -3411.698% |
| Agilent Technologies, Inc. | 4.91 Billion USD | -318.239% |
| OPKO Health, Inc. | 622.47 Million USD | -3204.369% |
| Homology Medicines, Inc. | 118.53 Million USD | -17252.973% |
| Geron Corporation | 146.12 Million USD | -13976.112% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | -407.811% |
| Exelixis, Inc. | 678.44 Million USD | -2931.786% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -102381.192% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -164005.633% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -8101.094% |
| Zoetis Inc. | 9.29 Billion USD | -121.291% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -5077.73% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -41727.314% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | -299.414% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -42358.458% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | -690.086% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | -755.175% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -17815.375% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -1147.013% |
| Blueprint Medicines Corporation | 918.64 Million USD | -2139.068% |
| Insmed Incorporated | 1.66 Billion USD | -1137.784% |
| TG Therapeutics, Inc. | 169.08 Million USD | -12064.887% |
| Incyte Corporation | 1.59 Billion USD | -1191.804% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -1634.902% |